Farming Industry Pharmaceuticals

Pharmaceuticals used by farming industry

Pharmaceuticals are used by the farming industry to control disease, the below list compares aquaculture pharmaceuticals approved by the Japanese Ministry of Agriculture, Forestry and Fisheries (MAFF) to those approved by the US Food and Drug Administration (US FDA). The World Health Organization Critically Important Antimicrobials (WHO CIA) list notes two pharmaceuticals approved by MAFF but not approved by the WHO.

Food and Drug Administration

The United States Food and Drug Administration (US FDA) will not allow the importation of fish that have been treated with drugs not approved by the FDA. There are just 9 pharmaceuticals that are FDA approved compared to 26 approved by the MAFF.

World Health Organization

The World Health Organization Critically Important Antimicrobials (WHO CIA). Use of CIA drugs can create antimicrobial resistant bacteria that can spread to humans through the food supply, limiting usage is an important step towards preserving the benefits of antimicrobials for people.

IngredientMAFF StatusFDA StatusWHO Status
Alkyl trimethyl ammoniumOK
Alkyl trimethyl ammonium calcium oxytetracycline OK
AmoxicillinOK
AmpicillinOKX
Bicoamycin benzoateOK
Chloramine-TOK
Chorionic gonadotropinOK
Doxycycline hydrochlorideOK
ErythromycinOKX
FlorfenicolOKOK
FormalinOK
Fosfomycin calciumOK
GlutathioneOK
Hydrogen peroxideOKOK
JosamycinOK
Lincomycin hydrochlorideOK
Lucium oxytetracyclineOK
Lysozyme chlorideOK
Oxolinic acidOK
Oxolinic acid (suspension-forming)OK
Oxytetracycline dihydrateOK
Oxytetracycline hydrochlorideOKOK
PraziquanteOK
Spiramycin embonateOK
Sulfadimethoxine/ormetoprimOK
SulfamerazineOK
Sulfamonomethoxine or its sodium saltOK
Sulfisozole sodiumOK
ThianphenicolOK
Tricaine methanesulfonateOK
Does not consider species, disease, or dosage
Source: Japan MAFF 28th Report on the Use of Marine Pharmaceuticals, 2015/01, US FDA Approved Aquaculture Drugs, 2020/04, WHO Critically Important Antimicrobials for Human Medicine, 6th revision, 2018